January 8, 2021 07:10 AM ESTUpdated 10:56 AM

Covid-19 roundup: Pfizer, BioNTech study suggest vaccine works against variants; Researchers say Sinovac's vaccine is 78% effective

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Amid heightened concerns about new, largely unknown variants of SARS-CoV-2 that appear to spread more rapidly, Pfizer and BioNTech say they have preliminary evidence that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Pfizer, BioNTech study suggest vaccine works against variants; Researchers say Sinovac's vaccine is 78% effective

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

CMS explains what went into its first round of drug price negotiations

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves subcutaneous version of Bristol Myers' Opdivo

Covid-19 roundup: Pfiz­er, BioN­Tech study sug­gest vac­cine works against vari­ants; Re­searchers say Sino­vac's vac­cine is 78% ef­fec­tive

Editor

Senior Editor

Sign up to read this article for free.

more like this

Covid-19 roundup: Pfizer, BioNTech study suggest vaccine works against variants; Researchers say Sinovac's vaccine is 78% effective